AAOI
Applied Optoelectronics, Inc.
AAOI has the edge over AEHR overall, supported by stronger valuation and stronger fundamentals.
AEHR
Aehr Test Systems
AEHR has slightly lower modeled downside risk, despite its lower overall score.
AAOI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
AAOI's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
AEHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Stable | |
| Under pressure | |
| Strong |
AEHR's revenue and balance sheet are currently strong, and its profitability is stable, but its cash flow is under pressure.
AAOI PE Valuation
AAOI has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 18x next year's earnings.
AEHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $0.69 | -99% |
| Fair | 44x | $2.18 | -96% |
| Expensive | 83x | $4.16 | -93% |
| Current | 1,221x | $61.04 | โ |
Historical ranges are pointers, not guarantees.
AEHR's PE is in its expensive range at 1221x.
AAOI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect AAOI to return to profit, with revenue growing. However, they disagree widely on these estimates.
AEHR Forward outlook
There aren't enough analyst estimates for AEHR to show an outlook.
AAOI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.98 | โ |
| Q3 2026 | -$0.42 | +$3.02 |
| Q2 2026 | -$0.77 | +$2.81 |
| Q1 2026 | -$0.65 | +$3.43 |
| Q4 2025 | -$0.64 | +$3.86 |
| Q3 2025 | -$3.44 | -$1.41 |
| Q2 2025 | -$3.58 | -$1.70 |
| Q1 2025 | -$4.08 | -$2.29 |
| Q4 2024 | -$4.50 | -$2.75 |
AAOI is still losing money, but far less than before: $0.42 per share over the past year, against $4.50 at its worst in late 2024.
AEHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.05 | +$0.27 |
| Q2 2026 | -$0.23 | -$0.10 |
| Q1 2026 | -$0.38 | -149% |
| Q4 2025 | -$0.30 | -140% |
| Q3 2025 | -$0.22 | -122% |
| Q2 2025 | -$0.13 | -112% |
| Q1 2025 | $0.78 | +50% |
| Q4 2024 | $0.75 | +5.6% |
AEHR has the edge over AAOI on earnings quality, reporting a profit while its opponent remains loss making.
AAOI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $269.9M | +127% |
| Q2 2026 | $191.9M | +86% |
| Q1 2026 | $151.1M | +51% |
| Q4 2025 | $134.3M | +34% |
| Q3 2025 | $118.6M | +82% |
| Q2 2025 | $103M | +138% |
| Q1 2025 | $99.9M | +146% |
| Q4 2024 | $100.3M | +66% |
AAOI has the edge over AEHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -0.5% | +15 points |
| Q2 2026 | -13% | +2.6 points |
| Q1 2026 | -8.6% | +0.3 points |
| Q4 2025 | -8.6% | -2.1 points |
| Q3 2025 | -15% | +10 points |
| Q2 2025 | -16% | +45 points |
| Q1 2025 | -8.9% | +44 points |
| Q4 2024 | -6.5% | +1 points |
AAOI's operating margin was โ0.5% last quarter, up 15 points from the same quarter a year ago, near the top of its range since 2019.
AEHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $33M | +201% |
| Q2 2026 | $18.8M | +34% |
| Q1 2026 | $10.3M | -44% |
| Q4 2025 | $9.9M | -27% |
| Q3 2025 | $11M | -16% |
| Q2 2025 | $14.1M | -15% |
| Q1 2025 | $18.3M | +142% |
| Q4 2024 | $13.5M | -37% |
AEHR's revenue is growing: $33M last quarter, up 201% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +55 points |
| Q2 2026 | -6.4% | +16 points |
| Q1 2026 | -41% | -35 points |
| Q4 2025 | -47% | -36 points |
| Q3 2025 | -37% | -38 points |
| Q2 2025 | -23% | -38 points |
| Q1 2025 | -6.1% | +21 points |
| Q4 2024 | -11% | -37 points |
AEHR has the edge over AAOI on profitability, with a higher operating margin.
AAOI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$369.9M | -$291.2M |
| Q2 2026 | -$265.3M | -$174.4M |
| Q1 2026 | -$143.6M | -$64.3M |
| Q4 2025 | -$104.6M | -$51.6M |
| Q3 2025 | -$78.7M | -$58M |
| Q2 2025 | -$91M | -$86M |
| Q1 2025 | -$79.3M | -$45.1M |
| Q4 2024 | -$53M | -$48.4M |
AAOI has burned cash in almost every quarter: โ$883M over the past year, against โ$302M the year before.
AEHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.1M | -$1.4M |
| Q2 2026 | $1.7M | +$6.8M |
| Q1 2026 | -$3.8M | -$502K |
| Q4 2025 | -$1.6M | +$4.6M |
| Q3 2025 | -$1.7M | -177% |
| Q2 2025 | -$5.1M | -535% |
| Q1 2025 | -$3.3M | -$174K |
| Q4 2024 | -$6.2M | -$5.5M |
AEHR has the edge over AAOI on cash flow, with more consistent year-over-year improvement.
AAOI Net Leverage
AAOI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AEHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -16.1x | Net Cash |
| Q4 2024 | -68.8x | Net Cash |
| Q3 2024 | -5.4x | Net Cash |
| Q2 2024 | -4.6x | Net Cash |
| Q1 2024 | -3.5x | Net Cash |
| Q4 2023 | -2.6x | Net Cash |
| Q3 2023 | -2.9x | Net Cash |
| Q2 2023 | -2.2x | Net Cash |
AEHR has more cash than debt.
AAOI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.1 | Neutral |
| Stochastic | 4.8 | Oversold |
AAOI's weekly RSI is 35 (neutral) and its Stochastic is 5 (oversold).
AEHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.9 | Neutral |
| Stochastic | 7.9 | Oversold |
AEHR's weekly RSI is 44 (neutral) and its Stochastic is 8 (oversold).
AAOI PE vs Technology Sector
AAOI has no meaningful PE right now: it lost money over the past year.
AEHR PE vs Technology Sector
| Metric | AEHR | Sector median | Relative |
|---|---|---|---|
| PE | 1,221x | 28x | 4,282% above |
| PE % | 100 | 35 | 65 pts above |
AEHR is trading at 1221x earnings, a 4282% premium to the Technology sector's median of 28x.
AAOI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.2 | 34% below |
| 20 week MA | $100.6 | 47% below |
| 50 week MA | $100.3 | 47% below |
| 100 week MA | $62.3 | 15% below |
| 200 week MA | $36.9 | 43% above |
AAOI has fallen below most of its moving averages, though it's still 43% above its 200-week average.
AEHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.7 | 16% below |
| 20 week MA | $82.8 | 26% below |
| 50 week MA | $66.6 | 8.3% below |
| 100 week MA | $41.3 | 48% above |
| 200 week MA | $32.9 | 85% above |
AEHR has the edge over AAOI on trend strength, trading above more of its moving averages.
AAOI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.5 | $8.77 | -24% |
| 2021 | $8.77 | $5.64 | -36% |
| 2022 | $5.64 | $1.95 | -65% |
| 2023 | $1.95 | $19.3 | +891% |
| 2024 | $19.3 | $37.7 | +95% |
| 2025 | $37.7 | $37.2 | -1.5% |
| 2026 YTD | $37.2 | $52.9 | +42% |
AAOI's yearly returns have swung widely, from +891% in 2023 to โ65% in 2022. It's up 42% so far in 2026.
AEHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.00 | $2.47 | +24% |
| 2021 | $2.47 | $20.5 | +729% |
| 2022 | $20.5 | $21.0 | +2.5% |
| 2023 | $21.0 | $26.5 | +26% |
| 2024 | $26.5 | $16.5 | -38% |
| 2025 | $16.5 | $21.5 | +30% |
| 2026 YTD | $21.5 | $61.0 | +184% |
AEHR has the edge over AAOI on returns for 2026, with the stronger performance.